Resources

This fact sheet provides aged care assessors with an overview of sharing My Aged Care support plans with My Health record, including their responsibility to ask for and record consent.

This document provides information for assessors about My Health Record, asking for and recording content, key contacts and useful links.

Aged care assessors should print this fact sheet and give it to older people during aged care assessments. It provides information for older people about sharing My Aged Care support plans with My Health record.

Aged care assessors can print this document and give it to older people during assessments. It provides information for older people about My Aged Care support plans, My Health Record, sharing support plans with My Health Record, key contacts and useful links.

This document provides information for healthcare providers about My Aged Care support plans being available in My Health Record.

The ATAGI 2024 Annual Statement on Immunisation is the fourth publication in this series. The statement highlights the key successes, trends and challenges in the use of vaccines and control of vaccine preventable diseases in Australia in 2023, and includes advice to address key issues for 2024.

Use these social media tiles to promote the changes to vaping in Australia from 1 October 2024.

This fact sheet contains information for prescribers on the changes to vaping in Australia.

This fact sheet contains information for parents and carers on the changes to vaping in Australia.

This fact sheet contains information on the changes to vaping in Australia.

This fact sheet provides advice to health professionals on the changes to Meningococcal ACWY vaccines under the National Immunisation Program (NIP).

This weekly report provides a snapshot of data on the impact of COVID-19 in residential aged care facilities nationally. The report includes data on the number of services impacted and number of staff and resident cases, as well as workforce, testing and PPE provided to affected services.

The Statement of Expectations sets out the role for the Aged Care Quality and Safety Commission in preparing the sector for the new Aged Care Act.

This report outlines the evaluation of evidence on the clinical effectiveness of naturopathy supplements as part of the Natural Therapies Review 2024.

This document outlines the updates to the LSDP’s testing requirements for Pompe disease, Gaucher disease (type 1), and mucopolysaccharidosis types I, II, and VI arising from the LSDP Expert Panel’s Medicines Reviews Recommendations.

This fact sheet supports care recipients to understand their monthly statement and the responsible use of Home Care Package funds. It accompanies the Care Recipient Guidance – Understanding your Home Care Package statement.

These guidelines contain the general, initial and ongoing eligibility requirements to access certain medications for Gaucher disease (type 1) under the Life Saving Drugs Program.

These guidelines contain the general, initial and ongoing eligibility requirements to access treatment for hereditary tyrosinaemia (type 1) under the Life Saving Drugs Program.

These guidelines contain the general, initial and ongoing eligibility requirements to access treatment for late-infantile onset Batten disease under the Life Saving Drugs Program.

These guidelines contain the general, initial and ongoing eligibility requirements to access treatment for infantile-onset or late-onset Pompe disease under the Life Saving Drugs Program.

These guidelines contain the general, initial and ongoing eligibility requirements to access treatment for mucopolysaccharidosis type I (MPS I) under the Life Saving Drugs Program.